Ignite Creation Date:
2025-12-25 @ 4:42 AM
Ignite Modification Date:
2025-12-26 @ 3:43 AM
Study NCT ID:
NCT02254018
Status:
COMPLETED
Last Update Posted:
2023-10-24
First Post:
2014-09-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2002-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2005-02-01
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2014-09-30
First Submit QC Date:
None
Study First Post Date:
2014-10-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-23
Last Update Post Date:
2023-10-24
Last Update Post Date Type:
ACTUAL